SeaStar Medical Announces 2026 Annual Meeting Results and Expansion of Equity Incentive Plan

SeaStar Medical Holding Corporation held its 2026 Annual Meeting of Stockholders on June 17, 2026. During the meeting, stockholders approved several key proposals. Notably, John Neuman was elected as a Class I director to serve until the 2029 annual meeting. Stockholders also approved an amendment and restatement of the Company’s 2022 Omnibus Incentive Plan. This amendment significantly increases the number of authorized shares of common stock reserved for issuance from 207,046 to 896,546 shares. This adjustment follows a previous 1-for-10 reverse stock split executed on January 5, 2026. Additionally, the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified. The 2022 Equity Incentive Plan is designed to align the interests of employees, directors, and consultants with those of stockholders by providing opportunities for equity-based compensation, including options, stock appreciation rights, and restricted stock units. No upcoming clinical trial result dates were disclosed in this filing.